Who Exports Nystatin from India — 223 Suppliers Behind a $52.3M Market
India's nystatin export market is supplied by 223 active exporters who collectively shipped $52.3M across 2,442 shipments. AGOG PHARMA LIMITED leads with a 20.4% market share, followed by ZYDUS LIFESCIENCES LIMITED and LINCOLN PHARMACEUTICALS LTD. The top 5 suppliers together control 60.1% of total export value, reflecting a concentrated market structure.
Top Nystatin Exporters from India — Ranked by Export Value
AGOG PHARMA LIMITED is the leading nystatin exporter from India, holding a 20.4% share of the $52.3M market across 2,442 shipments from 223 exporters. The top 5 suppliers — AGOG PHARMA LIMITED, ZYDUS LIFESCIENCES LIMITED, LINCOLN PHARMACEUTICALS LTD, MEDLEY PHARMACEUTICALS LIMITED, TORRENT PHARMACEUTICALS LTD — collectively control 60.1% of total export value, indicating a moderately concentrated market. Individual shares are: AGOG PHARMA LIMITED (20.4%), ZYDUS LIFESCIENCES LIMITED (12.2%), LINCOLN PHARMACEUTICALS LTD (10.9%), MEDLEY PHARMACEUTICALS LIMITED (8.6%), TORRENT PHARMACEUTICALS LTD (8.0%).
Top Nystatin Exporters from India
Ranked by export value · 223 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | AGOG PHARMA LIMITED PHARMACEUTICALS MEDICINES:NYSTAGO TABLETSNYST-VAN- NYSTATIN SUSPENSION 100000 IU/NYSTAGO TABLETS (NYSTATIN TABLETS BP 500 | $10.7M | 2 | 20.4% |
| 2 | ZYDUS LIFESCIENCES LIMITED NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $6.4M | 2 | 12.2% |
| 3 | LINCOLN PHARMACEUTICALS LTD NYSTATIN ORAL SUSPENSION USP 100000 UNINYSTATIN FOR ORAL SUSPENSION USP I LACNYST-VAN- NYSTATIN SUSPENSION 100000 IU/ | $5.7M | 11 | 10.9% |
| 4 | MEDLEY PHARMACEUTICALS LIMITED NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $4.5M | 1 | 8.6% |
| 5 | TORRENT PHARMACEUTICALS LTD NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $4.2M | 1 | 8.0% |
| 6 | VIVIMED LIFE SCIENCES PRIVATE LIMITED NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $1.3M | 1 | 2.4% |
| 7 | MACLEODS PHARMACEUTICALS LTD NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $1.2M | 6 | 2.2% |
| 8 | CADILA HEALTHCARE LIMITED NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $1.1M | 1 | 2.1% |
| 9 | ALEMBIC PHARMACEUTICALS LIMITED NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $988.1K | 1 | 1.9% |
| 10 | CAPLIN POINT LABORATORIES LIMITED | $976.5K | 5 | 1.9% |
| 11 | S KANT HEALTHCARE LIMITED PHARMACEUTICALS MEDICINES:NYSTAGO TABLETSNYSTATIN ORAL SUSPENSION USP 100000 UNINYSTATIN FOR ORAL SUSPENSION USP I LAC | $964.7K | 16 | 1.8% |
| 12 | TORRENT PHARMACEUTICALS LIMITED NYSTATIN ORAL SUSPENSION 100MU/ML, USPOTHER - NYSTATIN CREAM USP, 100000 UN/G,30G US NOS SIZE 30GNYSTATIN ORAL TABLETS USP[500000 UNITS | $805.1K | 1 | 1.5% |
| 13 | CIPLA LIMITED HARMLESS MEDICINE-NYSTATIN ORAL SUSPENSINYSTATIN 100,000 IU/ML ORAL SUSPENSION PNYSTATIN FOR ORAL SUSPENSION USP 100000 | $721.6K | 4 | 1.4% |
| 14 | MEDICAMEN BIOTECH LIMITED TIMEC NYSTATIN ORAL TABLETS BP 500000 IUTIMEC NYSTATIN VAGINAL TABLETS-(NYSTATINNYSTATIN ORAL SUSPENSION 234000 X 30 | $694.6K | 10 | 1.3% |
| 15 | VANSH REMEDIES NYST-VAN- NYSTATIN SUSPENSION 100000 IU/NYSTAGO TABLETS (NYSTATIN TABLETS BP 500NYSTATIN ORAL SUSPENSION USP 100000 UNIT | $632.0K | 3 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Nystatin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Approved | Yes | Yes | Multiple | Received FDA approval for enzalutamide tablets in October 2024; WHO-GMP and EU G |
| Lincoln Pharmaceuticals Limited | Not Listed | Yes | Yes | Not verified | Received EU GMP certification for Khatraj facility in May 2020; WHO-GMP certifie |
| Alembic Pharmaceuticals | Approved | Yes | Yes | 223 | Received multiple FDA approvals between 2024 and 2025; WHO-GMP and EU GMP certif |
| Cadila Pharmaceuticals Limited | Warning Letter, March 201 | Yes | Yes | Not verified | Received FDA warning letter in March 2014; WHO-GMP and EU GMP certified. |
| Intas Pharmaceuticals | Approved | Yes | Yes | Not verified | Acquired Teva's UK and Ireland assets in 2016; WHO-GMP and EU GMP certified. |
| S. Kant Healthcare Limited | Not Listed | Yes | Not Listed | Not verified | Approved by LMHRA through WHO-GMP desk audit. |
| Macleods Pharmaceuticals Ltd | Not Listed | Yes | Not Listed | Not verified | Approved by LMHRA through WHO-GMP desk audit. |
| Cipla Limited | Approved | Yes | Yes | Multiple | Received multiple FDA approvals; WHO-GMP and EU GMP certified. |
TransData Nexus reviewed the regulatory standing of 8 leading Nystatin exporters from India. 4 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 6 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Nystatin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% to the nation's bulk drug production. The city hosts a vast array of pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The establishment of Hyderabad Pharma City, recognized as a National Investment Manufacturing Zone in December 2019, further solidifies its position as a global pharmaceutical hub. This ecosystem provides a robust infrastructure for the production of active pharmaceutical ingredients (APIs) such as Nystatin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations industry, accounting for 33% of India's drug manufacturing and 28% of drug exports. Vadodara, in particular, is home to companies like Alembic Pharmaceuticals, which specializes in the production of formulations across various therapeutic areas. This region's focus on formulations makes it a strategic location for sourcing finished Nystatin products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. The region's well-established logistics and regulatory infrastructure support the efficient export of drugs like Nystatin, ensuring compliance with international standards.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. This region hosts numerous pharmaceutical companies that benefit from these incentives, making it an attractive location for cost-effective production. While not directly linked to Nystatin production, the cost advantages here could be leveraged for manufacturing related pharmaceutical products.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across Hyderabad and the Ahmedabad-Vadodara corridor to mitigate risks associated with supply chain disruptions.
- Leverage Export Infrastructure: Utilize the Mumbai-Thane-Raigad region's export facilities to ensure timely and compliant delivery of Nystatin to international markets.
- Monitor Regulatory Compliance: Ensure that all suppliers adhere to the standards set by the Central Drugs Standard Control Organisation (CDSCO) and the Directorate General of Foreign Trade (DGFT) to maintain product quality and regulatory compliance.
- Evaluate Cost Benefits: Consider the tax incentives offered in regions like Baddi-Nalagarh for potential cost savings in the production of Nystatin or related products.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Nystatin exporters from India
Zydus Lifesciences Limited — Zydus acquires Agenus' biologics manufacturing sites
In June 2025, Zydus Lifesciences acquired two biologics manufacturing facilities from Agenus, located in Emeryville and Berkeley, California, for $125 million. This acquisition marks Zydus' entry into the biologics contract development and manufacturing organization (CDMO) market. - IMPACT: This expansion may enhance Zydus' production capabilities, potentially increasing Nystatin exports.
Impact: This expansion may enhance Zydus' production capabilities, potentially increasing Nystatin exports.
Torrent Pharmaceuticals Ltd — Torrent acquires Curatio Healthcare for ₹2,000 crore
In September 2022, Torrent Pharmaceuticals acquired Curatio Healthcare, a skincare product manufacturer, for ₹2,000 crore. This acquisition aims to strengthen Torrent's presence in the dermatology segment. - IMPACT: While primarily focused on dermatology, this acquisition could indirectly affect Torrent's Nystatin production and export strategies.
Impact: While primarily focused on dermatology, this acquisition could indirectly affect Torrent's Nystatin production and export strategies.
Lincoln Pharmaceuticals Ltd — Lincoln's Gujarat plant receives Australia's TGA certification
In October 2021, Lincoln Pharmaceuticals' Gujarat manufacturing facility received certification from Australia's Therapeutic Goods Administration (TGA), enabling the company to export products to Australia. - IMPACT: This certification may open new markets for Lincoln's Nystatin exports, potentially increasing their global reach.
Impact: This certification may open new markets for Lincoln's Nystatin exports, potentially increasing their global reach.
Common Questions — Nystatin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which nystatin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, AGOG PHARMA LIMITED leads with 29 recorded shipments worth $10.7M. ZYDUS LIFESCIENCES LIMITED (207 shipments) and LINCOLN PHARMACEUTICALS LTD (53 shipments) are also established high-volume exporters.
Q How many nystatin manufacturers are there in India?
India has 223 active nystatin exporters with a combined export market of $52.3M across 2,442 shipments to 96 countries. The top 5 suppliers hold 60.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for nystatin from India?
Average FOB unit price: $26.10 per unit, ranging from $0.01 to $1563.41. Average shipment value: $21.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 223 verified Indian exporters of Nystatin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,442 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 96 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,442 Verified Shipments
223 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists